Edition:
United Kingdom

Imv Inc (IMV.TO)

IMV.TO on Toronto Stock Exchange

3.85CAD
19 Jul 2019
Change (% chg)

$-0.15 (-3.75%)
Prev Close
$4.00
Open
$4.06
Day's High
$4.15
Day's Low
$3.83
Volume
27,950
Avg. Vol
52,501
52-wk High
$8.49
52-wk Low
$3.58

Latest Key Developments (Source: Significant Developments)

Imv Inc Q1 Loss Per Share C$0.13
Thursday, 9 May 2019 

May 9 (Reuters) - Imv Inc ::. ANNOUNCES Q1 2019 FINANCIAL RESULTS AND CLINICAL PROGRAM ADVANCES.Q1 LOSS PER SHARE C$0.13.Q1 EARNINGS PER SHARE VIEW C$-0.16 -- REFINITIV IBES DATA.  Full Article

Imv Inc Says Data From A Clinical Study Shows DPX-Survivac As A Potential Monotherapy Treatment For Advanced Ovarian Cancer
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Imv Inc ::INITIAL PHASE 2 DATA FROM AN IMV CLINICAL STUDY CONTINUES TO DEMONSTRATE DPX-SURVIVAC’S PRIOR TREND AS A POTENTIAL MONOTHERAPY TREATMENT FOR ADVANCED OVARIAN CANCER.IMV INC - 83% OF SUBJECTS (5 OF 6) SHOW STABLE DISEASE (SD), INCLUDING TWO TUMOR REGRESSIONS.IMV INC - 80% (4 OF 5) WITH STABLE DISEASE ARE IN SUBJECTS WITH A LOWER BASELINE TUMOR BURDEN (BTB).  Full Article

Imv Inc Files Preliminary Prospectus Supplement For Proposed Public Offering Of Common Shares
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Imv Inc ::IMV INC. FILES PRELIMINARY PROSPECTUS SUPPLEMENT FOR PROPOSED PUBLIC OFFERING OF COMMON SHARES.IMV INC - INTENDS TO USE NET PROCEEDS OF OFFERING TO ACCELERATE DEVELOPMENT OF DPX-SURVIVAC IN COMBINATION WITH KEYTRUDA.  Full Article

Imv announces Q3 results
Friday, 2 Nov 2018 

Nov 2 (Reuters) - Imv Inc ::IMV INC. ANNOUNCES Q3 2018 FINANCIAL RESULTS AND INVESTOR CONFERENCE CALL DETAILS.IMV INC - QTRLY LOSS PER SHARE $0.14.IMV INC - FORECASTS CASH BURN RATE TO BE BETWEEN $4-MILLION AND $4.5-MILLION FOR LAST QUARTER OF 2018.  Full Article

IMV Announces Early Positive Results From Phase 2 Clinical Trial Of Lead Candidate DPX-Survivac In Combination With Merck’S Keytruda In Patients With DLBCL
Tuesday, 18 Sep 2018 

Sept 18 (Reuters) - Imv Inc ::IMV INC. ANNOUNCES EARLY POSITIVE RESULTS FROM PHASE 2 CLINICAL TRIAL OF LEAD CANDIDATE DPX-SURVIVAC IN COMBINATION WITH MERCK’S KEYTRUDA® IN PATIENTS WITH DLBCL.IMV INC - DATA SHOWED TWO OF FIRST FOUR EVALUABLE PARTICIPANTS SHOWED TUMOR REGRESSIONS AT FIRST ON-TREATMENT CT SCAN.IMV INC - IN TRIAL, COMBINATION THERAPY APPEARS TO DEMONSTRATE AN ACCEPTABLE SAFETY PROFILE, WITH NO SERIOUS ADVERSE EVENTS REPORTED TO DATE.IMV INC - FIRST ENROLLED PARTICIPANT DEMONSTRATED A TUMOR REGRESSION OF 48% AT FIRST ON-TREATMENT SCAN.IMV INC - SECOND PARTICIPANT DEMONSTRATED A PARTIAL RESPONSE (PR) VIA A TUMOR REGRESSION OF 66% AT FIRST ON-TREATMENT SCAN.IMV INC - PRELIMINARY DATA FROM THIRD PARTICIPANT IN TRIAL OF DPX-SURVIVAC IN COMBINATION WITH KEYTRUDA DEMONSTRATED STABLE DISEASE.IMV INC - FOURTH PARTICIPANT HAD EARLY DISEASE PROGRESSION LESS THAN TWO MONTHS FOLLOWING TREATMENT INITIATION AND WAS DISCONTINUED FROM STUDY.  Full Article

IMV Inc Files For Mixed Shelf Of Upto $150 Mln
Thursday, 31 May 2018 

May 31 (Reuters) - Imv Inc ::IMV INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Immunovaccine Announces $12.5 Million Bought Deal Offering
Thursday, 25 Jan 2018 

Jan 25 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES $12.5 MILLION BOUGHT DEAL OFFERING.IMMUNOVACCINE INC - ENTERED INTO BOUGHT DEAL FINANCING AGREEMENT TO SELL 6.3 MILLION COMMON SHARES AT A PRICE OF $2.00 PER COMMON SHARE.  Full Article

Immunovaccine announces positive clinical data from its collaborative combination immunotherapy trial in advanced ovarian cancer
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER.IMMUNOVACCINE INC - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL​ SHOW A 70% DISEASE CONTROL RATE DATA.IMMUNOVACCINE - EXPECTS TO PROVIDE CLINICAL UPDATE ON SECOND DOSING COHORT OF DPX-SURVIVAC IN FIRST HALF OF 2018.IMMUNOVACCINE - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL FOR DPX-SURVIVAC​DEMONSTRATE TOLERABLE SAFETY PROFILE.  Full Article

Immunovaccine reports qtrly loss per share of ‍$0.02​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Immunovaccine Inc :Immunovaccine announces third quarter 2017 financial results.Immunovaccine Inc qtrly loss per share ‍$0.02​.  Full Article

Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Immunovaccine Inc ::Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac in combination with Merck's checkpoint inhibitor Pembrolizumab in DLBCL.  Full Article